"Vincristinum"@en . . . . . . . . . "Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). "@en . . . . . . . "# Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8608515 # Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17355029 # JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14070392 # FDA label # Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10226730"@en . " "@en . . . . . . . . "The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca²⁺-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis."@en . . . "IVN-RAT LD₅₀ 1300 mg/kg; IPR-MUS LD₅₀ 5.2 mg/kg. Marqibo\u00AE must only be administered IV because it is fatal if administered by other routes. Marqibo\u00AE also has different dosing than vincristine sulphate injection, so attention is needed to prevent overdoses. The most clinically significant adverse effect of vincristine is neurotoxicity. "@en . . . . . "Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone\u2013marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). "@en . "When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours. "@en . "The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine. "@en . "investigational"@en . . . . . . . "Leurocristine"@en . . "57-22-7"@en . "22-Oxovincaleukoblastine"@en . "Homer L. Pearce, \"Method of preparing vincristine.\" U.S. Patent US4303584, issued November, 1967."@en . "Vincristina"@en . "22-Oxovincaleukoblastin"@en . . "Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound."@en . "Vincristin"@en . "~75%"@en . . . . . . . "Humans and other mammals"@en . . "approved"@en . . . . . . . . . . . . . . . . . . . "Vincristine"@en . . . " "@en . . .